MARKET

DRRX

DRRX

DURECT
NASDAQ
0.8000
-0.0060
-0.74%
Closed 16:00 03/28 EDT
OPEN
0.8151
PREV CLOSE
0.8060
HIGH
0.8151
LOW
0.8000
VOLUME
12.92K
TURNOVER
--
52 WEEK HIGH
1.880
52 WEEK LOW
0.7010
MARKET CAP
24.83M
P/E (TTM)
-3.1434
1D
5D
1M
3M
1Y
5Y
1D
DURECT Corporation’s Earnings Call Highlights Cost Cuts and Breakthrough Potential
TipRanks · 2d ago
DURECT CORPORATION ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024
Press release · 2d ago
HC Wainwright & Co. Reiterates Neutral on Durectto Neutral
Benzinga · 2d ago
H.C. Wainwright Sticks to Its Hold Rating for Durect (DRRX)
TipRanks · 2d ago
Northland Securities Reaffirms Their Buy Rating on Durect (DRRX)
TipRanks · 2d ago
DURECT Corporation Reports 2024 Financial Results and Updates
TipRanks · 3d ago
DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis
Seeking Alpha · 3d ago
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 3d ago
More
About DRRX
More
DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.
Recently
Symbol
Price
%Change

Webull offers DURECT Corp stock information, including NASDAQ: DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.